My Treatment Approach to Rheumatoid Arthritis

Slides:

Advertisements

Similar presentations

( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.

Advertisements

BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.

Disease modified Anti-rheumatic drugs ( DMARD)

My Treatment Approach to Hairy Cell Leukemia Rahul R. Naik, MD, Alan Saven, MD Mayo Clinic Proceedings Volume 87, Issue 1, Pages (January 2012) DOI:

From: Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic AgentsA Cost-Effectiveness.

Rheumatoid arthritis The Lancet

My Treatment Approach to Gout

My Treatment Approach to Rheumatoid Arthritis

Recommendations for the treatment of established RA (disease duration 6 month or longer). Biologic, biological originator DMARD or boDMARD; DMARD, disease-modifying.

Pleomorphic Adenoma in the Parotid Gland

Prediction of Response to Targeted Treatment in Rheumatoid Arthritis

Drug Therapy of Rheumatoid Arthritis

Ductal Carcinoma in Situ of the Breast

Vibeke Strand, MD, MACR, Jasvinder A. Singh, MD, MPH

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Diagnostic Approach to the Complexity of IgG4-Related Disease

Crohn Disease: Epidemiology, Diagnosis, and Management

Advances in the Treatment of Metastatic Prostate Cancer

William L. Lanier, MD Mayo Clinic Proceedings

Desmoid Tumor Mayo Clinic Proceedings

Shireen Mirza, MBBS, Roberto Benzo, MD Mayo Clinic Proceedings

Improving the Recognition and Diagnosis of Fibromyalgia

Management of Adult Onset Seizures

My Treatment Approach to Gout

Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New Anagha Bangalore Kumar, MBBS, Rachel Maus, PhD,

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD,

Hidradenitis Suppurativa

What’s new in my specialty- Rheumatoid Arthritis

Understanding Palliative Care and Hospice

Untitled by Martin Blank

Gestational Trophoblastic Disease

Topical Analgesics in the Management of Acute and Chronic Pain

The Organ Transplant Imperative

Acupuncture Mayo Clinic Proceedings

Association between anti-CCP antibody status and response to remission, LDA and mACR by anti-CCP status and TNFi initiators (multivariable models). Association.

Infections and Biologic Therapy in Rheumatoid Arthritis

Photodynamic Therapy for Early Stage Central Type of Lung Cancer

Pancreatic Ductal Adenocarcinoma

Rheumatology Practice at Mayo Clinic: The First 40 Years–1920 to 1960

Mean change from baseline CDAI in abatacept and TNFi initiators with a typical patient profile. Mean change from baseline CDAI in abatacept and TNFi initiators.

Mean change from baseline in disease and disability outcomes at 6 months for TNFi initiators by anti-CCP status. Mean change from baseline in disease and.

Pharmacogenomics: Precision Medicine and Drug Response

Classic Hodgkin Lymphoma

Scott I. Kahan, MD, MPH Mayo Clinic Proceedings

Management of Adult Onset Seizures

Pleomorphic Adenoma in the Parotid Gland

Renal Pyelocalyceal Squamous Cell Carcinoma

Evaluation and Management of Penicillin Allergy

Rheumatoid Arthiritis

Institutional Review Boards: What Clinician Researchers Need to Know

Diabetic Mastopathy Mayo Clinic Proceedings

Hepatocellular Carcinoma

Down River by Charles Munch

Postoperative Trouble

Pancreatic Tumor in a Patient With Parathyroid and Pituitary Disease

Medical Treatment of Overactive Bladder: In Response

Nat. Rev. Rheumatol. doi: /nrrheum

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Mantle Cell Involvement of the Spleen

Squamous Cell Carcinoma of the Tongue

Trends in Prevalence of Functional Disability in Rheumatoid Arthritis Compared With the General Population Elena Myasoedova, MD, PhD, John M. Davis,

Current Concepts in Laboratory Testing to Guide Antimicrobial Therapy

Minnesota Birds and Flora by Emily Wilson

Sotirios Tsiodras, MD, MSc, ScD, George Samonis, MD, Dimitrios T

Diagnosis and Management of Headache in Older Adults

Mayo Clinic Proceedings 2012: “A New Era in Journal Stewardship”

Biologic DMARDs and targeted synthetic DMARDs approved for the treatment of rheumatoid arthritis. Biologic DMARDs and targeted synthetic DMARDs approved.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Presentation transcript:

My Treatment Approach to Rheumatoid Arthritis John M. Davis, MD, Eric L. Matteson, MD, MPH Mayo Clinic Proceedings Volume 87, Issue 7, Pages 659-673 (July 2012) DOI: 10.1016/j.mayocp.2012.03.011 Copyright © 2012 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 1 Our treatment approach to newly diagnosed rheumatoid arthritis (RA) from baseline to 6 months of follow-up. ACR/EULAR 2010 = American College of Rheumatology/European League Against Rheumatism 2010 Classification Criteria for RA; CDAI = Clinical Disease Activity Index; CTLA4:Ig = cytotoxic T lymphocyte–associated antigen 4:immunoglobulin fusion protein; HCQ = hydroxychloroquine; LEF = leflunomide; MTX = methotrexate; Rx = prescription; SC = subcutaneous; SDAI = Simplified Disease Activity Index; SSZ = sulfasalazine; TNF = tumor necrosis factor. Mayo Clinic Proceedings 2012 87, 659-673DOI: (10.1016/j.mayocp.2012.03.011) Copyright © 2012 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 2 Our treatment approach to early rheumatoid arthritis (RA) from 6 months to 1 year. anti–IL-6R = anti-interleukin 6 receptor; CDAI = Clinical Disease Activity Index; CTLA4:Ig = cytotoxic T lymphocyte–associated antigen 4:immunoglobulin fusion protein; DMARD = disease-modifying antirheumatic drug; HCQ = hydroxychloroquine; mAb = monoclonal antibody; MTX = methotrexate; Rx = prescription; SC = subcutaneous; SDAI = Simplified Disease Activity Index; SSZ = sulfasalazine; TNF = tumor necrosis factor. Mayo Clinic Proceedings 2012 87, 659-673DOI: (10.1016/j.mayocp.2012.03.011) Copyright © 2012 Mayo Foundation for Medical Education and Research Terms and Conditions

FIGURE 3 Our approach to treatment of rheumatoid arthritis (RA) beyond the first year of disease. DMARD therapy refers to use of methotrexate (MTX) and other conventional disease-modifying antirheumatic drugs. Biologic therapy refers to treatment with tumor necrosis factor (TNF) inhibitors, abatacept, rituximab, tocilizumab, or anakinra. anti–IL-6R = anti-interleukin 6 receptor; CDAI = Clinical Disease Activity Index; CTLA4:Ig = cytotoxic T lymphocyte–associated antigen 4:immunoglobulin fusion protein; HCQ = hydroxychloroquine; IL-1ra = interleukin 1 receptor antagonist; LEF = leflunomide; mAb = monoclonal antibody; Rx = prescription; SDAI = Simplified Disease Activity Index; SSZ = sulfasalazine. Mayo Clinic Proceedings 2012 87, 659-673DOI: (10.1016/j.mayocp.2012.03.011) Copyright © 2012 Mayo Foundation for Medical Education and Research Terms and Conditions